These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

529 related articles for article (PubMed ID: 21554150)

  • 1. Efficacy and safety of adalimumab treatment in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.
    Poddubnyy D; Rudwaleit M
    Expert Opin Drug Saf; 2011 Jul; 10(4):655-73. PubMed ID: 21554150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adalimumab for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis - a five-year update.
    Poddubnyy D; Rudwaleit M
    Expert Opin Biol Ther; 2013 Nov; 13(11):1599-611. PubMed ID: 24074224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Golimumab: a new anti-TNF-alpha agent for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
    Voulgari PV
    Expert Rev Clin Immunol; 2010 Sep; 6(5):721-33. PubMed ID: 20828280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Autoimmune aspects of treatment with TNF-alpha inhibitors].
    Kolarz B; Targońska-Stepniak B; Darmochwał-Kolarz D; Majdan M
    Postepy Hig Med Dosw (Online); 2007 Aug; 61():478-84. PubMed ID: 17786135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis.
    Bonafede M; Joseph GJ; Princic N; Harrison DJ
    J Med Econ; 2013 Sep; 16(9):1120-8. PubMed ID: 23808901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease.
    Burmester GR; Panaccione R; Gordon KB; McIlraith MJ; Lacerda AP
    Ann Rheum Dis; 2013 Apr; 72(4):517-24. PubMed ID: 22562972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings.
    Bonafede M; Fox KM; Watson C; Princic N; Gandra SR
    Adv Ther; 2012 Aug; 29(8):664-74. PubMed ID: 22886712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effectiveness and safety of biological therapy with adalimumab].
    Fehér J; Lengyel G
    Orv Hetil; 2009 Jun; 150(26):1215-22. PubMed ID: 19546078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Golimumab: A novel anti-TNF-alpha human monoclonal antibody for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
    Campas-Moya C
    Drugs Today (Barc); 2010 Jan; 46(1):13-22. PubMed ID: 20200692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
    Barra L; Pope JE; Payne M
    J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.
    Minozzi S; Bonovas S; Lytras T; Pecoraro V; González-Lorenzo M; Bastiampillai AJ; Gabrielli EM; Lonati AC; Moja L; Cinquini M; Marino V; Matucci A; Milano GM; Tocci G; Scarpa R; Goletti D; Cantini F
    Expert Opin Drug Saf; 2016 Dec; 15(sup1):11-34. PubMed ID: 27924643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experiences on the use of biological drugs in psoriatic arthritis-associated amyloidosis.
    Immonen K; Kauppi M; Hakala M
    Scand J Rheumatol; 2011 May; 40(3):236-8. PubMed ID: 21231814
    [No Abstract]   [Full Text] [Related]  

  • 13. An examination of the mechanisms involved in secondary clinical failure to adalimumab or etanercept in inflammatory arthropathies.
    Bandrés Ciga S; Salvatierra J; López-Sidro M; García-Sánchez A; Durán R; Vives F; Raya-Álvarez E
    J Clin Rheumatol; 2015 Apr; 21(3):115-9. PubMed ID: 25807089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.
    Bonovas S; Minozzi S; Lytras T; González-Lorenzo M; Pecoraro V; Colombo S; Polloni I; Moja L; Cinquini M; Marino V; Goletti D; Matucci A; Tocci G; Milano GM; Scarpa R; Cantini F
    Expert Opin Drug Saf; 2016 Dec; 15(sup1):35-54. PubMed ID: 27924644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Cantini F; Niccoli L; Nannini C; Cassarà E; Kaloudi O; Giulio Favalli E; Becciolini A; Benucci M; Gobbi FL; Guiducci S; Foti R; Mosca M; Goletti D
    Semin Arthritis Rheum; 2017 Oct; 47(2):183-192. PubMed ID: 28413099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-tumour necrosis factor treatment increases circulating T helper type 17 cells similarly in different types of inflammatory arthritis.
    Hull DN; Williams RO; Pathan E; Alzabin S; Abraham S; Taylor PC
    Clin Exp Immunol; 2015 Sep; 181(3):401-6. PubMed ID: 25766640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease.
    Cepeda EJ; Williams FM; Ishimori ML; Weisman MH; Reveille JD
    Ann Rheum Dis; 2008 May; 67(5):710-2. PubMed ID: 18079191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions.
    Sfikakis PP
    Curr Dir Autoimmun; 2010; 11():180-210. PubMed ID: 20173395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retention on anti-tumour necrosis factor therapy: the Waikato experience.
    Ip K; Hartley L; Solanki K; White D
    N Z Med J; 2015 May; 128(1415):34-40. PubMed ID: 26117510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?
    Rossini M; Viapiana O; Orsolini G; Fracassi E; Idolazzi L; Gatti D; Adami S; Govoni M
    Reumatismo; 2015 Mar; 66(4):285-303. PubMed ID: 25829189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.